{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:11:34Z","timestamp":1793160694226,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.gim.2025.101670","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:52:12Z","timestamp":1766130732000},"page":"101670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world outcomes of vosoritide in achondroplasia: A systematic review and meta-analysis of multinational clinical evidence"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2097-3290","authenticated-orcid":false,"given":"Anna Luiza Braga","family":"Albuquerque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Inez","family":"Dacoregio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cain\u00e3 Gon\u00e7alves","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9bora Romeo","family":"Bertola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Victor","family":"Zattar Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gim.2025.101670_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41574-021-00595-x","article-title":"International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia","volume":"18","author":"Savarirayan","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.gim.2025.101670_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0092-8674(94)90302-6","article-title":"Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia","volume":"78","author":"Shiang","year":"1994","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.gim.2025.101670_bib3","article-title":"ACMG Therapeutics Committee6\u2217documents@acmg.net. Vosoritide approved for treatment of linear growth in pediatric patients with achondroplasia: a therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)","volume":"1","author":"Poskanzer","year":"2023","journal-title":"Genet Med Open"},{"key":"10.1016\/j.gim.2025.101670_bib4","doi-asserted-by":"crossref","DOI":"10.1159\/000543743","article-title":"Real-world safety and effectiveness of vosoritide in children with achondroplasia: French early access program","author":"Cormier-Daire","year":"2025","journal-title":"Horm Res Paediatr"},{"issue":"5","key":"10.1016\/j.gim.2025.101670_bib5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41574-024-01074-9","article-title":"International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia","volume":"21","author":"Savarirayan","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"10252","key":"10.1016\/j.gim.2025.101670_bib6","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","article-title":"Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial","volume":"396","author":"Savarirayan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.gim.2025.101670_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076335","article-title":"Updated recommendations for the Cochrane Rapid Review Methods Guidance for Rapid Reviews of Effectiveness","volume":"384","author":"Garritty","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.gim.2025.101670_bib8","author":"Higgins"},{"key":"10.1016\/j.gim.2025.101670_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.gim.2025.101670_bib11","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2019"},{"key":"10.1016\/j.gim.2025.101670_bib12","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"suppl 3","key":"10.1016\/j.gim.2025.101670_bib13","first-page":"161","article-title":"Vosoritide therapy in 16 young children with achondroplasia: a retrospective study","volume":"97","author":"Adachi","year":"2024","journal-title":"Horm Res Paediatr"},{"issue":"suppl 3","key":"10.1016\/j.gim.2025.101670_bib14","first-page":"293","article-title":"Single center prospective study on the efficacy and safety of vosoritide therapy in achondroplasia: a comprehensive evaluation at three and six months","volume":"97","author":"Leonardi","year":"2024","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.gim.2025.101670_bib30","first-page":"108","article-title":"Treatment of patients with achondroplasia in the Republic of Croatia \u2013 first experiences and results","volume":"69","author":"Kero","year":"2025","journal-title":"Paediatr Croat"},{"issue":"12","key":"10.1016\/j.gim.2025.101670_bib15","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/s41436-021-01287-7","article-title":"Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study","volume":"23","author":"Savarirayan","year":"2021","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.gim.2025.101670_bib22","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf041","article-title":"Real-world outcome of vosoritide treatment in children with achondroplasia: a 12-month retrospective observational study","volume":"9","author":"Reincke","year":"2025","journal-title":"J Endocr Soc"},{"issue":"1","key":"10.1016\/j.gim.2025.101670_bib27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S2352-4642(23)00265-1","article-title":"Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"8","author":"Savarirayan","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"issue":"suppl 3","key":"10.1016\/j.gim.2025.101670_bib16","first-page":"348","article-title":"Real-world experience with vosoritide treatment in achondroplasia: a single-center report from Turkey","volume":"97","author":"Abali","year":"2024","journal-title":"Horm Res Paediatr"},{"issue":"suppl 2","key":"10.1016\/j.gim.2025.101670_bib17","article-title":"Vosoritide therapy in children with achondroplasia: early experience in an Italian cohort","volume":"8","author":"Allegri","year":"2024","journal-title":"JBMR Plus"},{"issue":"suppl 3","key":"10.1016\/j.gim.2025.101670_bib18","first-page":"341","article-title":"Vosoritide therapy in children with achondroplasia: single-center experience","volume":"97","author":"Amin","year":"2024","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.gim.2025.101670_bib19","first-page":"636","article-title":"Real-world data: effectiveness and safety of vosoritide in the treatment of achondroplasia in Chinese population","volume":"110","author":"Chen","year":"2025","journal-title":"Endocr Abstr"},{"issue":"suppl 3","key":"10.1016\/j.gim.2025.101670_bib21","first-page":"38","article-title":"Expansion of the CrescNet registry achondroplasia module: real-world demographic data and outcomes after up to 2 years of vosoritide treatment","volume":"97","author":"Mohnike","year":"2024"},{"issue":"8","key":"10.1016\/j.gim.2025.101670_bib23","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1007\/s12325-025-03223-6","article-title":"Real-world safety and effectiveness of vosoritide in achondroplasia: results from a Single Center in Portugal","volume":"42","author":"Rua","year":"2025","journal-title":"Adv Ther"},{"issue":"12","key":"10.1016\/j.gim.2025.101670_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101274","article-title":"Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of life","volume":"26","author":"Savarirayan","year":"2024","journal-title":"Genet Med"},{"issue":"12","key":"10.1016\/j.gim.2025.101670_bib24","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.gim.2022.08.015","article-title":"Growth parameters in children with achondroplasia: a 7-year, prospective, multinational, observational study","volume":"24","author":"Savarirayan","year":"2022","journal-title":"Genet Med"},{"key":"10.1016\/j.gim.2025.101670_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.115872","article-title":"Lifetime impact of achondroplasia: current evidence and perspectives on the natural history","volume":"146","author":"Hoover-Fong","year":"2021","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.gim.2025.101670_bib26","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1210\/clinem\/dgaf017","article-title":"Approach to the patient with achondroplasia-new considerations for diagnosis, management, and treatment","volume":"110","author":"Merchant","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gim.2025.101670_bib28","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1016\/j.pedn.2024.04.007","article-title":"Exploring the family experience of children aged 2-4 years receiving daily vosoritide injections: a qualitative study","volume":"77","author":"Dentry","year":"2024","journal-title":"J Pediatr Nurs"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109836002500317X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109836002500317X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:28:02Z","timestamp":1781767682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109836002500317X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S109836002500317X"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2025.101670","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes of vosoritide in achondroplasia: A systematic review and meta-analysis of multinational clinical evidence","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2025.101670","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Medical Genetics and Genomics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101670"}}